Highest-materiality recent filing
Bio-Rad Q1 GAAP net loss $527M ($19.55/share); net sales +1.1% to $592.1M
Net sales $592.1M, up 1.1% YoY; GAAP gross margin 52.3% (flat YoY), non-GAAP gross margin 53.1%.
Bio-Rad Q4 GAAP operating loss $118.9M; non-GAAP EPS down to $2.51 from $2.90
Q4 GAAP operating loss $118.9M vs income $58.4M YoY; gross margin down 140bps to 49.8%.
Bio-Rad posts GAAP net loss of $342M in Q3 2025; non-GAAP EPS rises to $2.26
Revenue $653.0M, up slightly from $649.7M year-over-year.
Bio-Rad Q2 revenue up 2% to $652M; completes Stilla acquisition
Q2 2025 revenue $651.6M (+2.1% YoY); GAAP net income $317.8M vs loss $2,165.5M (prior year included Sartorius losses).
Bio-Rad Q1 revenue falls 4% to $585M; full-year 2025 outlook moderated on uncertainty
Revenue $585.4M, down from $610.8M YoY; GAAP gross margin 52.3% vs 53.4%.
Bio-Rad Q4 revenue down 2%; launches restructuring (5% workforce cut) and offers to acquire Stilla
Q4 2024 revenue $667.5M vs $681.2M YoY; GAAP operating income $58.4M vs $95.3M.
Bio-Rad Q3 revenue up 2.8% to $649.7M; net income $653.2M on Sartorius gain
Net sales $649.7M, +2.8% YoY; currency-neutral +3.4%; Clinical Diagnostics grew 5.6% to $388.8M.
Bio-Rad appoints Jon DiVincenzo as President and COO, replacing retiring Andy Last
DiVincenzo joins from Labcorp, where he was EVP and President, Central Laboratories & International.
Bio-Rad Q2 net sales down 6.3% YoY; Life Science weak, Diagnostics up 2.1%; board adds $500M buyback
Q2 net sales $638.5M, -6.3% YoY; Life Science $250.5M (-16.5%), Diagnostics $387.9M (+2.1%).
Bio-Rad Q1 net sales down 9.8% to $610.8M; Life Science segment falls 25.3% YoY
Net sales $610.8M, down 9.8% YoY (currency-neutral -9.6%); operating income $44.7M vs $61.9M.
Bio-Rad discloses Sartorius AG FY 2023 results: revenue €3.4B, net profit €290M
Sartorius AG FY 2023 sales revenue €3,395.7M, gross profit €1,567.1M.
Bio-Rad Q4 sales down 6.7% YoY; Life Science segment declines 19.1%
Q4 net sales $681.2M, down 6.7% YoY; currency-neutral sales down 7.7%.
Bio-Rad EVP & President of Clinical Diagnostics Group to resign effective Jan 12, 2024
Dara Grantham Wright notified resignation to pursue another opportunity, effective Jan 12, 2024.
Bio-Rad Q3 net sales down 7.1% YoY to $632.1M; lowers full-year 2023 outlook
Net sales $632.1M, down 7.1% YoY; currency-neutral decline 7.9%; COVID sales dropped to $0.3M from $17.2M.
Bio-Rad CFO Ilan Daskal to resign effective Nov 6, 2023; search initiated
CFO Ilan Daskal notified Bio-Rad of his resignation to pursue another opportunity.
Bio-Rad Q2 net loss $1.16B on investment swings; lowers FY2023 outlook on softer biopharma demand
Net sales $681.1M, down 1.4% (0.3% currency-neutral); ex-COVID revenue up 4.6% currency-neutral.
Bio-Rad Q1 sales down 3.3% to $676.8M; operating income drops 57.7% to $61.9M
Net sales $676.8M, down 3.3%; currency-neutral down 0.3%; ex-COVID up 6.1%.
Bio-Rad Q4 revenue flat YoY; non-GAAP EPS $3.31, guides FY2023 ~6-7% growth
Q4 net sales $730.3M, -0.3% reported; currency-neutral +5.8% (+10.6% ex-COVID).
Bio-Rad Q3 sales $680.8M (-8.9% YoY); non-GAAP EPS $2.60 vs $3.71; FY22 guidance reaffirmed
Q3 net sales $680.8M, down 8.9% YoY; currency-neutral core sales (ex-COVID and legal settlements) grew 6.1%.
Q2 GAAP net loss $927M ($31.12/diluted) vs income $914M ($30.32) last year; non-GAAP net income $101M ($3.38) vs $107M ($3.54).
Bio-Rad Q1 revenue $700.1M (-3.7% YoY); core ex-COVID up 6.5%; non-GAAP EPS $4.94 vs $5.21
GAAP net loss $3.37B from Sartorius fair value change; non-GAAP net income $149.1M.
Bio-Rad targets ~9% core revenue CAGR, 28% adj. EBITDA margin by 2025 at Investor Day
Core revenue CAGR target of ~9% from 2021 to 2025, excluding COVID-related sales and currency effects.
Q4 2021 sales $732.8M (-7.2% YoY); Life Science sales down 23.8% on lower COVID-related qPCR demand.
Bio-Rad loans €400M to Sartorius-Herbst at 1.5% plus appreciation rights
Loan of €400 million to Sartorius-Herbst Beteiligungen II GmbH at 1.5% per annum plus value appreciation rights.
Bio-Rad Q3 revenue $747M (+15.4% YoY); non-GAAP EPS $3.71; raises FY21 guidance
Life Science segment revenue $373.5M (+15.3% YoY); Clinical Diagnostics $372.2M (+15.5% YoY).
On August 20, 2024, Bio-Rad Laboratories, Inc. (the “Company”) announced the appointment by the Board of Directors of the Company of Jonathan P. DiVincenzo as the Company’s President and Chief Operating Officer (including as principal operating officer), effective September 9, 2024.
Dr. Last will be retiring from his position on September 5, 2024.
Effective on Mr. DiVincenzo’s September 9, 2024 start date as the Company’s President and Chief Operating Officer, Norman Schwartz will continue as the Company’s Chief Executive Officer and Chairman of the Board and will no longer be the Company’s President.
On April 26, 2024, the Company disclosed that Roop K. Lakkaraju, the Company’s Executive Vice President and Chief Financial Officer (and principal financial officer) will act as the Company’s principal accounting officer.
On April 22, 2024, Simon May, the Executive Vice President and President, Life Science Group, of Bio-Rad Laboratories, Inc. (the “Company”) and a named executive officer of the Company, notified the Company of his plans to resign from the Company to pursue another opportunity, effective as of May 1, 2024.
On April 24, 2024, James J. Barry, currently the Company’s Senior Vice President of Global Manufacturing, was appointed to the position of Executive Vice President and President, Life Science Group, effective May 1, 2024.
On April 10, 2024, Dr. Andrew Last, the Executive Vice President, Chief Operating Officer (and principal operating officer) of Bio-Rad Laboratories, Inc. (the “Company”), notified the Company that he intends to retire from his position by early September 2024.
On March 20, 2024, Bio-Rad Laboratories, Inc. (the “Company”) announced the appointment by the Board of Directors of the Company of Roop K. Lakkaraju as the Company’s Executive Vice President, Chief Financial Officer (including as principal financial officer), effective April 15, 2024.
On February 9, 2024, the Company’s board of directors appointed Norman Schwartz, the Company’s President and Chief Executive Officer and the Chairman of the Board, as the Company’s principal financial officer until a permanent replacement for Mr. Daskal has been appointed.
Ilan Daskal resigned from his position as the Company’s Executive Vice-President, Chief Financial Officer and the Company’s principal financial officer in order to pursue other opportunities.
On December 4, 2023, Dara Grantham Wright, the Executive Vice-President and President, Clinical Diagnostics Group, of Bio-Rad Laboratories, Inc. (the “Company”) and a named executive officer of the Company, notified the Company of her plans to resign from the Company to pursue another opportunity, effective at the close of business on January 12, 2024.
On October 12, 2023, Ilan Daskal, the Executive Vice-President, Chief Financial Officer of Bio-Rad Laboratories, Inc. (the “Company”) and the Company’s principal financial officer, notified the Company of his plans to resign from the Company to pursue another opportunity, effective at the close of business on November 6, 2023.
Max materiality 0.80 · Median 0.57 · Most common event earnings